BioLife Solutions corrects Q2 earnings; raises full-year revenue guidance to $99-101M

BIOLIFE SOLUTIONS INC

2024-Q2 EPS reported -$0.68 revenue$55,107,000

Q2 total revenue $28.3M, down 3% YoY but up 6% sequentially; Cell Processing up 11% sequentially.
GAAP net loss from continuing ops $7.1M (incl $4.1M write-off) versus $5.5M loss a year ago.
Non-GAAP adjusted EBITDA $4.8M or 17% of revenue, up from $1.7M or 6% in Q2 2023.
FY 2024 total revenue guidance raised to $99-101M; Cell Processing guidance raised to $70-71M.
8-K/A corrects prior release to reduce stock compensation by $2.1M from discontinued operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.